Evidence map›Paper›PMID 32545904›Full record

ArticleCancers2020

Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia.

Lindsey T Brinton, Steven Sher, Katie Williams, Daniel Canfield, Shelley Orwick, Ronni Wasmuth, Casey Cempre, Jordan Skinner, Amy Lehman, James S Blachly and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Lindsey T BrintonDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Steven SherDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-3788-3228
Katie WilliamsDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Daniel CanfieldDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Shelley OrwickDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Ronni WasmuthDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Casey CempreDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Jordan SkinnerDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Amy LehmanCenter for Biostatistics, The Ohio State University, Columbus, OH 43210, USA.
James S BlachlyDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
John C ByrdDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Rosa LapalombellaDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
The Ohio State University · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · US

Funding

Targeted Therapy for LeukemiaR35CA197734 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2015 to 2021
$6.6M
Grant of Equipment from StorageReview.com NANCI NIH HHS R35 CA197734NIH HHS 5P30CA016058NIH HHS 5R01CA223165NIH HHS R35 CA197734
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a hematopoietic stem-cell-derived leukemia with often successive derived driver mutations. Late onset acquisition of internal tandem duplication in

Indexed as

AMLCRISPR-Cas9 screeningFLT3synergismXPO1

Identifiers

PMID32545904
PMCPMC7352446
OpenAlexW3035446967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.